Abstract

This study aimed to investigate the association between preadmission statin use and acute kidney injury (AKI) incidence among critically ill patients who needed admission to the intensive care unit (ICU) for medical care. Medical records of patients admitted to the ICU were reviewed. Patients who continuously took statin for >1 month prior to ICU admission were defined as statin users. We investigated whether preadmission statin use was associated with AKI incidence within 72 h after ICU admission and whether the association differs according to preadmission estimated glomerular filtration rate (eGFR; in mL min−1 1.73 m−2). Among 21,236 patients examined, 5756 (27.1%) were preadmission statin users and 15,480 (72.9%) were non-statin users. Total AKI incidence within 72 h after ICU admission was 31% lower in preadmission statin users than in non-statin users [odds ratio (OR), 0.69; 95% confidence interval (CI), 0.61–0.79; p < 0.001]. This association was insignificant among individuals with eGFR <30 mL min−1 1.73 m−2 (p > 0.05). Our results suggested that preadmission statin therapy is associated with a lower incidence of AKI among critically ill patients; however, this effect might not be applicable for patients with eGFR <30 mL min−1 1.73 m−2.

Highlights

  • Acute kidney injury (AKI) is defined as a rapid worsening of renal functions [1] and affects2–18% of inpatients and 57% of critical care patients [2,3,4]

  • The exclusion criteria were as follows: (1) patients with an estimated glomerular filtration rate of

  • Considering that baseline kidney function is a risk factor of AKI [21], we investigated the interaction between estimated glomerular filtration rate (eGFR) before ICU admission and preadmission statin use, and when there was an interaction, we performed a subgroup analysis by dividing the participants according to eGFR (≥90, 60–90, 30–60, and

Read more

Summary

Introduction

Acute kidney injury (AKI) is defined as a rapid worsening of renal functions [1] and affects. 2–18% of inpatients and 57% of critical care patients [2,3,4]. AKI in critically ill patients in the intensive care unit (ICU) is an important issue because it delays recovery and increases hospital mortality [5]. Appropriately preventing AKI in the ICU is currently an important task in ICU patient management [6]. Known as a 3-hydroxy-3-methylglutaryl-coenzyme A inhibitor, is one of the most commonly prescribed drugs worldwide [7] that lowers the risk of cardiovascular death by.

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.